FDA Category 2 Update: The 5 Peptides Still Facing Heavy Review As excitement builds around peptides potentially moving off the FDA Category 2 list, it's important to understand one key reality: Not FDA approvals February 2026 2024 FDA approvals exceed average number but have lower sales projections CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 FDA A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are Public Meeting: FDA Rare Disease Day 2026 02 23 2026 FDA